Europska Unija - hrvatski - EMA (European Medicines Agency)

mirum pharmaceuticals international b.v. - maralixibat chloride - alagille syndrome - other drugs for bile therapy - livmarli is indicated for the treatment of cholestatic pruritus in patients with alagille syndrome (algs) 2 months of age and older.

Europska Unija - hrvatski - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - hepatitis a virus (inactivated), hepatitis b surface antigen - immunization; hepatitis b; hepatitis a - cjepiva - twinrix pedijatrijskih je indiciran za uporabu u sobe imunološki dojenčadi, djece i adolescenata od jedne godine do i uključujući 15 godina koji su u opasnosti od oba hepatitisa a i hepatitisa b infekcije.

Europska Unija - hrvatski - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - dostarlimab - endometrial neoplasms - antineoplastic agents and antibody drug conjugates - jemparli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dmmr)/microsatellite instability-high (msi h) recurrent or advanced endometrial cancer (ec) that has progressed on or following prior treatment with a platinum-containing regimen.

Europska Unija - hrvatski - EMA (European Medicines Agency)

marinus pharmaceuticals emerald limited - ganaxolone - epileptic syndromes; spasms, infantile - drugi antiepileptici sredstva - ztalmy is indicated for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (cdkl5) deficiency disorder (cdd) in patients 2 to 17 years of age. ztalmy may be continued in patients 18 years of age and older.

Europska Unija - hrvatski - EMA (European Medicines Agency)

mylan ireland limited - dimetil fumarat - multipla skleroza, Рецидивно-Ремиттирующее - imunosupresivi - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

mundipharma gesellschaft m.b.h., wiedner gurtel 13, turm 24, og 15, beč, austrija - fluticasonum, formoterolum - stlačeni inhalat, suspenzija - 125 mikrograma/5 mikrograma - urbroj: jedna odmjerena doza (doza koja izlazi iz ventila) sadrži:125 mikrograma flutikazonpropionata i 5 mikrograma formoterolfumarat dihidrata, što odgovara isporučenoj dozi (dozi koja se oslobađa iz aktivatora) od približno 115 mikrograma flutikazonpropionata i 4,5 mikrograma formoterolfumarat dihidrata

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

mundipharma gesellschaft m.b.h., wiedner gurtel 13, turm 24, og 15, beč, austrija - fluticasonum, formoterolum - stlačeni inhalat, suspenzija - 50 mikrograma/5 mikrograma - urbroj: jedna odmjerena doza (doza koja izlazi iz ventila) sadrži: 50 mikrograma flutikazonpropionata i 5 mikrograma formoterolfumarat dihidrata, što odgovara isporučenoj dozi (dozi koja se oslobađa iz aktivatora) od približno 46 mikrograma flutikazonpropionata i 4,5 mikrograma formoterolfumarat dihidrata

Europska Unija - hrvatski - EMA (European Medicines Agency)

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - lijekovi koji se koriste u dijabetesu - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 i 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

pliva d.o.o.sarajevo - tacrolimus - kapsula s produljenim oslobađanjem, tvrda - 0,5 mg/1 kapsula - 1 kapsula s produljenim oslobađanjem, tvrda sadrž: 0,5 mg takrolimusa (u obliku hidrata).

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

pliva d.o.o.sarajevo - tacrolimus - kapsula s produljenim oslobađanjem, tvrda - 3 mg/1 kapsula - 1 kapsula s produljenim oslobađanjem, tvrda sadrži: 3 mg takrolimusa (u obliku hidrata)